Carna Biosciences Inc represents a set of core values and a strong corporate philosophy. The company prioritizes innovation, constantly pushing the boundaries of biomedical research and drug discovery. With a focus on delivering cutting-edge solutions, Carna Biosciences is dedicated to developing highly selective kinase inhibitors and providing exceptional scientific expertise to its global clientele. Committed to fostering collaborations and partnerships, Carna Biosciences aims to accelerate the development of transformative therapeutics to address significant unmet medical needs. The company's emphasis on integrity, excellence, and collaboration drives its mission to improve human health and make a meaningful impact in the field of life sciences.

Carna Biosciences Inc is primarily present in the United States and Japan.

Carna Biosciences Inc has achieved several significant milestones. Firstly, the company successfully advanced its lead kinase inhibitor, CP-547,632, into clinical development for the treatment of cancer and inflammatory diseases. Additionally, Carna Biosciences Inc collaborated with multiple pharmaceutical companies to discover and develop novel kinase inhibitors. The company also established a strong portfolio of over 80 proprietary kinase inhibitors, showcasing its research and development capabilities. Moreover, Carna Biosciences Inc expanded its global presence by opening a subsidiary in Cambridge, UK, enhancing its ability to provide innovative solutions in the field of drug discovery.

Carna Biosciences Inc is a renowned biopharmaceutical company known for its comprehensive portfolio of innovative drug discovery solutions. Established in (insert year), Carna Biosciences has a rich history in developing breakthrough therapies to address unmet medical needs. With a focus on kinase biology, the company has become a global leader in kinase-targeted drug discovery. Carna Biosciences' cutting-edge research, state-of-the-art technology, and experienced team have made significant contributions to the pharmaceutical industry, advancing therapeutic interventions for various diseases. Through strategic collaborations and a commitment to scientific excellence, Carna Biosciences continues to drive advancements in personalized medicine for the benefit of patients worldwide.

The main competitors of Carna Biosciences Inc in the market include companies like Merck & Co., Inc., Novartis AG, and Pfizer Inc. These companies are also engaged in the development and commercialization of innovative drugs and therapies. However, Carna Biosciences Inc stands out with its unique focus on kinase drug discovery and development. With its expertise and strong commitment to advancing kinase biology, Carna Biosciences Inc continues to differentiate itself from competitors and create value for its shareholders.

Carna Biosciences Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Carna Biosciences Inc is focused on developing and commercializing innovative kinase inhibitor drugs. As a leading provider of kinase biology expertise, the company utilizes their extensive knowledge and scientific capabilities to discover and develop small molecule drugs that target kinases involved in various diseases. By leveraging their proprietary technological platforms and collaborations with pharmaceutical partners, Carna Biosciences aims to advance the field of kinase biology and contribute to the development of novel therapeutics.

Коефициентът на цена спрямо печалбата (КЦП) на Carna Biosciences е 2,63.

Коефициентът на цена към оборот (KUV) на Carna Biosciences е 1,54.

AlleAktien качественият резултат за Carna Biosciences е 5/10.

очаквана Carna Biosciences оборотът е 3,74 млрд. JPY.

очаквана Carna Biosciences печалба е 2,19 млрд. JPY.

Carna Biosciences Inc is a leading company in the field of drug discovery, based in Kobe, Japan. The company was founded in 2003 by a group of researchers specializing in the discovery and development of new drugs. Carna Biosciences aims to develop highly specific drugs targeting kinase enzymes. Kinase enzymes play an important role in cell signaling. They are crucial for various biological processes, such as cell division and differentiation, as well as the regulation of metabolic processes. Dysfunctions of kinase enzymes can lead to various diseases, including cancer, inflammation, and autoimmune diseases. Carna Biosciences offers a wide range of products and services for drug discovery. The product range includes over 500 different enzymes, including kinase enzymes, phosphatases, proteases, and other drug targets. The enzymes are offered in various forms, from recombinant proteins to cell-free purified enzymes. Carna Biosciences is also a leading provider of drug screening services. The company offers a comprehensive platform for the identification of new drugs, including high-throughput screening and structure-based design. By utilizing these resources, researchers can identify and optimize potential drugs in a short period of time. Additionally, Carna Biosciences has developed several proprietary technologies that can facilitate and enhance drug discovery. The kinase activity measurement technology "KNIME" enables rapid and reliable identification of kinase activity inhibitors. The "SPRINT" technology (Structure-Prediction-Informed NMR and optimization Technology) allows structure-based optimization of drugs to increase their efficacy. Carna Biosciences is divided into various business units, each focused on specific areas of drug discovery. For example, the "Targeted Kinase Inhibitors" division focuses on the development of new drugs against cancer and inflammatory diseases. The "Protein-Protein Interaction Inhibitors" division develops drugs that selectively inhibit the interaction between proteins involved in certain diseases. The "Epigenetic Modulators" division develops drugs for the modulation of epigenetic mechanisms involved in the development of various diseases. Overall, Carna Biosciences' business model is based on the development and commercialization of highly specific drugs targeting specific enzymes and proteins. By providing a wide range of products and services for drug discovery, the company has established a reputation in the research community. Additionally, Carna Biosciences is proud to be a driving force in the development of new technologies and approaches in drug discovery to accelerate the discovery and development of new drugs.

Carna Biosciences разпределя дивидента от 0 JPY на плащания годишно.

Дивидентата за Carna Biosciences в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Carna Biosciences е JP3220550002.

WKN на Carna Biosciences е A0NHD5.

Тикерът на Carna Biosciences е 4572.T.

През последните 12 месеца Carna Biosciences изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Carna Biosciences да изплати дивиденда в размер на 0 JPY.

Дивидентната доходност на Carna Biosciences в момента е .

Carna Biosciences изплаща дивидент на тримесечие. Той се разпределя в месеците .

Carna Biosciences платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 JPY. Това съответства на дивидентна доходност от 0 %.

Carna Biosciences се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Carna Biosciences на 12.08.2024 г. в размер на 0 JPY, трябваше да притежавате акцията в портфейла си преди Ex-деня на 12.08.2024 г..

Последното дивидентно плащане беше извършено на 12.08.2024 г..

През година 2023 Carna Biosciences изплати 0 JPY под формата на дивиденти.

Дивидентите от Carna Biosciences се изплащат в JPY.